Drug Approval | January 21, 2022
Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
It plans to deliver over 300 million doses to the Indian government
Flattish volume growth and subdued new launches were key factors for last month
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Subscribe To Our Newsletter & Stay Updated
